In clinical practice, the main anti-cancer drugs regulated for esophageal cancer are as follows: 1. chemotherapeutic drugs, such as paclitaxel and docetaxel of paclitaxel class, fluorouracil, tegeo, capecitabine of fluorouracil class, carboplatin, cisplatin, oxaliplatin, irinotecan, epi-amycin, etc. 2. anti-tumor angiogenesis drugs, such as apatinib, anlotinib, etc. 3. molecular targeting drugs, such as 4. immune checkpoint inhibitors, such as pablizumab, nabritumomab, tremelimumab, etc. 5. adjuvant treatment with Chinese herbal medicines that have certain anti-cancer or anti-cancer effects. In conclusion, the above mentioned anti-cancer drugs should be reasonably and appropriately selected by the attending clinicians according to the stage of the tumor, the patient’s physical condition, and the patient’s and family’s compliance.